Soluble Tumour Necrosis Factor-α Receptor I and Interleukin-6 as Markers of Activity in Thyrotoxic Graves' Disease

Pichler, Robert; Maschek, W; Hatzl-Griesenhofer, M; Huber, Heiko; Crespillo-Gómez, C; Berg, Jörg

doi:10.1055/s-2003-41624

Cited by 16 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reuter et al . showed a significant correlation between elevated sTNF-R1 levels and increased levels of FT4, FT3, TRAb and thyroidal Tc-99m uptake in 39 hyperthyroid patients ( 29 ). Similar findings were reported by Díez et al .…”

Section: Resultsmentioning

confidence: 98%

See 1 more Smart Citation

Serum concentrations of TNF-α and its soluble receptors in Graves’ disease

Zhu

Wang

et al. 2020

Endocrine Connections

View full text Add to dashboard Cite

Graves' disease (GD), an organ-specific autoimmune disease, is the most common cause of hyperthyroidism. Tumour necrosis factor-alpha (TNF-α) exhibits immunological and metabolic activities involved in the induction and maintenance of immune responses. We attempted to evaluate the relationship between GD and serum TNF-α and its soluble receptors (sTNFRs), soluble tumour necrosis factor receptor 1 and 2 (sTNF-R1 and sTNF-R2). A total of 72 GD patients and 72 matched healthy individuals were recruited for this study. Serum TNF-α and sTNFRs were measured by sandwich ELISA. In our study, no significant difference was observed in TNF-α, but sTNFRs were found to be significantly elevated in GD patients compared to healthy individuals. Serum sTNFR levels were positively correlated with free triiodothyronine (FT3) and free thyroxine (FT4), and TNF-α was negatively correlated with thyroid-stimulating hormone (TSH) in the GD group. It was also shown that thyrotropin receptor antibody (TRAb) was positively correlated with TNF-α and sTNFRs. Spearman’s correlation analysis showed that only sTNF-R1 was positively correlated with complement C3. Multiple linear regression analysis suggests that serum levels of sTNF-R1 and FT4 may play an important role in the serum level of FT3. According to the median value of FT3 level, GD patients were further divided into a high FT3 group and a low FT3 group. The serum levels of sTNF-R1 in the high FT3 GD group were significantly higher than those in the low FT3 GD group. In conclusion, sTNFRs may play an important role in anti-inflammatory and immune response in GD.

show abstract

Section: Resultsmentioning

confidence: 98%

“…Only a few studies have included the measurements of serum levels of soluble cytokine receptors such as sTNF-R1 ( 2 , 26 , 27 , 28 , 29 ) and sTNF-R2 ( 30 ). Reuter et al .…”

Section: Resultsmentioning

confidence: 99%

Serum concentrations of TNF-α and its soluble receptors in Graves’ disease

Zhu

Wang

et al. 2020

Endocrine Connections

View full text Add to dashboard Cite

show abstract

“…One study demonstrated that serum TNF-α levels are elevated in patients with TAO, but not in those with GD without TAO [37]. Serum TNF-α and soluble TNF receptor levels are elevated in patients with newly diagnosed GD, and decrease following correction of hyperthyroidism [40]. Gene polymorphism analyses have demonstrated that single nucleotide polymorphisms (SNPs) of the TNF-α gene are associated with TAO in Japanese and Iranian populations [41, 42].…”

Section: Cytokine Pathways Potentially Relevant To Taomentioning

confidence: 99%

Cytokines as villains and potential therapeutic targets in thyroid-associated ophthalmopathy: from bench to bedside

Rajaii

McCoy

Smith

2014

Expert Review of Ophthalmology

View full text Add to dashboard Cite

Summary The pathophysiology underlying Graves’ disease and its ocular manifestation, thyroid associated ophthalmopathy (TAO) is incompletely understood. Characterization of the mononuclear cells driving the disease and the cytokines they produce has led to significant advances in our understanding of TAO. This in turn has resulted in the identification of potentially attractive drug targets. For instance, development of inhibitors of specific cytokine pathways for use in other autoimmune diseases now presents an opportunity for their application in TAO. In this paper, we review the rationale for considering anti-cytokine therapy in TAO, evidence linking specific cytokines such as interleukin-6, tumor necrosis factor-α, and interleukin-17 pathways to TAO, and explore the potential for targeting of these pathways as therapy.

show abstract

Serum levels of the interferon-γ-inducible α chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy

Antonelli

Fallahi

Rotondi

et al. 2006

British Journal of Surgery

View full text Add to dashboard Cite

Serum levels of CXCL10 are higher in newly diagnosed hyperthyroid patients with Graves' disease than in those with toxic nodular goitre, and decrease when euthyroidism is achieved with antithyroid therapy. This high level may be related to the active inflammatory phase of Graves' disease. A further reduction of CXCL10 levels after thyroidectomy indicates that it is produced mainly in the thyroid in patients with autoimmune thyroid disease.

show abstract

Soluble Tumour Necrosis Factor-α Receptor I and Interleukin-6 as Markers of Activity in Thyrotoxic Graves' Disease

Cited by 16 publications

References 18 publications

Serum concentrations of TNF-α and its soluble receptors in Graves’ disease

Serum concentrations of TNF-α and its soluble receptors in Graves’ disease

Cytokines as villains and potential therapeutic targets in thyroid-associated ophthalmopathy: from bench to bedside

Serum levels of the interferon-γ-inducible α chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy

Contact Info

Product

Resources

About